Chemotherapy for breast cancer in pregnancy: Evidence and guidance for oncologists

Therapeutic Advances in Medical Oncology

Volumn 3, Issue 2, 2011, Pages 73-83

  Mcgrath, Sophie E ^a   Ring, Alistair ^a  

^a ROYAL SUSSEX COUNTY HOSPITAL   (United Kingdom)

Author keywords

breast cancer; chemotherapy; pregnancy

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; LAPATINIB; METHOTREXATE; NAVELBINE; ONDANSETRON; PACLITAXEL; PAMIDRONIC ACID; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; VINCA ALKALOID;

ADJUVANT THERAPY; ADVANCED CANCER; ALOPECIA; AMBIGUOUS GENITALIA; ANEMIA; APNEA; BIRTH DEFECT; BLOOD VESSEL FISTULA; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER INVASION; CARDIOTOXICITY; CLEFT PALATE; CLUBFOOT; CRANIOFACIAL MALFORMATION; CYTOTOXICITY; DOWN SYNDROME; DRUG EFFECT; ESOPHAGUS ATRESIA; FEBRILE NEUTROPENIA; FETUS DEATH; FETUS DEVELOPMENT; FETUS MALFORMATION; FIRST TRIMESTER PREGNANCY; GASTROESOPHAGEAL REFLUX; GESTATIONAL AGE; GOLDENHAR SYNDROME; GONAD DYSFUNCTION; HEMANGIOMA; HOLOPROSENCEPHALY; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; IMMUNOGLOBULIN A DEFICIENCY; INFERTILITY; INTRAUTERINE GROWTH RETARDATION; KIDNEY FAILURE; KIDNEY POLYCYSTIC DISEASE; LETHARGY; LIMB MALFORMATION; LUNG CANCER; MULTIPLE CYCLE TREATMENT; NAUSEA; NECROTIZING ENTEROCOLITIS; NEUROBLASTOMA; NEUTROPENIA; OLIGOHYDRAMNIOS; ORGANOGENESIS; OSTEOPOROSIS; OTITIS MEDIA; OVARY CANCER; PARESTHESIA; PNEUMONIA; PREECLAMPSIA; PREGNANCY; PREMATURE LABOR; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; PYLORUS STENOSIS; RASH; RECURRENT CANCER; RESPIRATORY FAILURE; REVIEW; RISK BENEFIT ANALYSIS; SECOND TRIMESTER PREGNANCY; SEPSIS; SIDE EFFECT; SMALL FOR DATE INFANT; SPONTANEOUS ABORTION; SUBARACHNOID HEMORRHAGE; TERATOGENICITY; THIRD TRIMESTER PREGNANCY; THROMBOCYTOPENIA; THYROID CANCER; TRISOMY 18; VESICOURETERAL REFLUX;

EID: 79952849211     PISSN: 17588340     EISSN: 17588359     Source Type: Journal    
DOI: 10.1177/1758834010392445     Document Type: Review

References (97)

1. Agrawal V. David R.J. Harris V.J. (2003) Classification of acute respiratory disorders of all newborns in a tertiary care centre. J Natl Med Assoc 95: 585–595.
2. Anderson J.M. (1979) Mammary cancers and pregnancy. BMJ 1: 1124–1127.
3. Avilés A. Neri N. (2001) Hematological malignancies and pregnancy: a final report of 84 children who received chemotherapy in utero. Clin Lymphoma 2: 173–177.
4. Azim H.A. Jr Peccatori F.A. Scarfone G. Acaia B. Rossi P. Cascio R. et al (2008) Anthracyclines for gestational breast cancer: course and outcome of pregnancy. Ann Oncol 19: 1511–1512.
5. Azim H.A. Jr Peccatori F.A. Liptrott S.J. Catania C. Goldhirsch A. (2009) Breast cancer and pregnancy: how safe is trastuzumab? Nat Rev Clin Oncol 6: 367–370.
6. Aziz S. Pervez S. Khan S. Siddiqui T. Kayani N. Israr M. et al (2003) Case control study of novel prognostic markers and disease outcome in pregnancy/lactation-associated breast carcinoma. Pathol Res Pract 199: 15–21.
7. Bader A.A. Schlembach D. Tamussino K.F. Pristauz G. Petru E. (2007) Anhydramnios associated with administration of trastuzumab and Paclitaxel for metastatic breast cancer during pregnancy. Lancet Oncol 8: 79–81.
8. Bawle E.V. Conard J.V. Weiss L. (1998) Adult and two children with fetal methotrexate syndrome. Teratology 57: 51–55.
9. Beale J.M. Tuohy J. McDowell S.J. (2009) Herceptin (trastuzumab) therapy in a twin pregnancy with associated oligohydramnios. Am J Obstet Gynecol 201: e13–e14.
10. Berry D.L. Theriault R.L. Holmes F.A. Parisi V.M. Booser D.J. Singletary S.E. et al (1999) Management of breast cancer during pregnancy using a standardized protocol. J Clin Oncol 17: 855–861.
11. Berveiller P. Mir O. Sauvanet E. Antoine E.C. Goldwasser F. (2008) Ectopic pregnancy in a breast cancer patient receiving trastuzumab. Reprod Toxicol 25: 286–288.
12. Bonadonna G. Gianni L. Santoro A. Bonfante V. Bidoli P. Casali P. et al (1993) Drugs ten years later: epirubicin. Ann Oncol 4: 359–369.
13. Bonnier P. Romain S. Dilhuydy J.M. Bonichon F. Julien J.P. Charpin C. et al (1997) Influence of pregnancy on the outcome of breast cancer: a case-control study. Societe Francaise de Senologie et de Pathologie Mammaire Study Group. Int J Cancer 72: 720–727.
14. Cardonick E. Dougherty R. Grana G. Gilmandyar D. Ghaffar S. Usmani A. (2010) Breast cancer during pregnancy: maternal and fetal outcomes. Cancer J 16: 76–82.
15. Clark R.M. Chua T. (1989) Breast cancer and pregnancy: the ultimate challenge. Clin Oncol (R Coll Radiol) 1: 11–18.
16. Cullins S.L. Pridjian G. Sutherland C.M. (1994) Goldenhar's syndrome associated with taxoxifen given to the mother during gestation. JAMA 271: 1905–1906.
17. de Carolis S. Grimolizzi F. Garofalo S. Fatigante G. Ferrazzani S. Carducci B. et al (2006) Cancer in pregnancy: results of a series of 32 patients. Anticancer Res 26: 2413–2418.
18. de Santis M. Lucchese A. de Carolis S. Ferrazani S. Caruso A. (2000) Metastatic breast cancer in pregnancy: first case of chemotherapy with docetaxel. Eur J Cancer Care (Engl) 9: 235–237.
19. Djokanovic N. Klieger-Grossmann C. Koren G. (2008) Does treatment with bisphosphonates endanger the human pregnancy? J Obstet Gynaecol Can 30: 1146–1148.
20. Doll D.C. Ringenberg Q.S. Yarbro J.W. (1989) Antineoplastic agents and pregnancy. Semin Oncol 16: 337–346.
21. Dunlop D.J. Soukop M. McEwan H.P. (1990) Antenatal administration of aminopropylidene diphosphonate. Ann Rheum Dis 49: 955–956.
22. Ebert U. Löffler H. Kirch W. (1997) Cytotoxic therapy and pregnancy. Pharmacol Ther 74: 207–220.
23. Elledge R.M. Ciocca D.R. Langone G. McGuire W.L. (1993) Estrogen receptor, progesterone receptor, and HER-2/neu protein in breast cancers from pregnant patients. Cancer 71: 2499–2506.
24. Espié M. Cuvier C. (1998) Treating breast cancer during pregnancy. What can be taken safely? Drug Saf 18: 135–142.
25. Ezzat A. Raja M.A. Berry J. Zwaan F.E. Jamshed A. Rhydderch D. et al (1996) Impact of pregnancy on non-metastatic breast cancer: a case control study. Clin Oncol (R Coll Radiol) 8: 367–370.
26. Fanale M.A. Uyeu A.R. Theriault R.L. Adam K. Thompson R.A. (2005) Treatment of metastatic breast cancer with trastuzumab and vinorelbine during pregnancy. Clin Breast Cancer 6: 354–356.
27. Furr B.J. Valcaccia B. Challis J.R. (1976) The effects of Nolvadex (tamoxifen citrate; ICI 46,474) on pregnancy in rabbits. J Reprod Fertil 48: 367–369.
28. Gadducci A. Cosio S. Fanucchi A. Nardini V. Roncella M. Conte P.F. et al (2003) Chemotherapy with epirubicin and Paclitaxel for breast cancer during pregnancy: case report and review of the literature. Anticancer Res 23: 5225–5229.
29. Garber J.E. (1989) Long-term follow-up of children exposed in utero to antineoplastic agents. Semin Oncol 16: 437–444.
30. García-Manero M. Royo M.P. Espinos J. Pina L. Alcazar J.L. López G. (2009) Pregnancy associated breast cancer. Eur J Surg Oncol 35: 215–218.
31. Gemignani M.L. Petrek J.A. Borgen P.I. (1999) Breast cancer and pregnancy. Surg Clin North Am 79: 1157–1169.
32. German Breast Group. (2010) GBG-29: Breast cancer in pregnancy. Prospective register study for the diagnosis and treatment of breast cancer in pregnancy. www.germanbreastgroup.de/pregnancy (accessed 12 August 2010).
33. Giacalone P.L. Laffargue F. Benos P. (1999) Chemotherapy for breast carcinoma during pregnancy: a French national survey. Cancer 86: 2266–2272.
34. Gililland J. Weinstein L. (1983) The effects of cancer chemotherapeutic agents on the developing fetus. Obstet Gynecol Surv 38: 6–13.
35. Glantz J.C. (1994) Reproductive toxicology of alkylating agents. Obstet Gynecol Surv 49: 709–715.
36. Gonzalez-Angulo A.M. Walters R.S. Carpenter R.J. Jr Ross M.I. Perkins G.H. Gwyn K. et al (2004) Paclitaxel chemotherapy in a pregnant patient with bilateral breast cancer. Clin Breast Cancer 5: 317–319.
37. Gralla R.J. Osoba D. Kris M.G. Kirkbride P. Hesketh P.J. Chinnery L.W. et al (1999) Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 17: 2971–2994.
38. Hahn K.M. Johnson P.H. Gordon N. Kuerer H. Middleton L. Ramirez M. et al (2006) Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero. Cancer 107: 1219–1226.
39. Halaska M.J. Pentheroudakis G. Strand P. Stankusova H. Chod J. Robova H. et al (2009) Presentation, management and outcome of 32 patients with pregnancy-associated breast cancer: a matched controlled study. Breast J 15: 461–467.
40. Illidge T.M. Hussey M. Godden C.W. (1996) Malignant hypercalcaemia in pregnancy and antenatal administration of intravenous pamidronate. Clin Oncol (R Coll Radiol) 8: 257–258.
41. Isaacs R.J. Hunter W. Clark K. (2001) Tamoxifen as systemic treatment of advanced breast cancer during pregnancy–case report and literature review. Gynecol Oncol 80: 405–408.
42. Ishida T. Yokoe T. Kasumia F. Sakamoto G. Makita M. Tominaga T. et al (1992) Clinicopathologic characteristics and prognosis of breast cancer patients associated with pregnancy and lactation: analysis of case–control study in Japan. Jpn J Cancer Res 83: 1143–1149.
43. Kalter H. Warkany J. (1983) Congenital malformations etiologic factors and their role in prevention. Parts I and II. N Engl J Med 308: 424–431, 491–497.
44. Kelly H. Graham M. Humes E. Dorflinger L.J. Boggess K.A. O'Neil B.H. et al (2006) Delivery of a healthy baby after first-trimester maternal exposure to lapatinib. Clin Breast Cancer 7: 339–341.
45. Kushari J. Mukherjea M. (1980) Studies on beta-glucuronidase of the developing human placenta. Gynecol Obstet Invest 11: 119–127.
46. Lee K.F. Simon H. Chen H. Bates B. Hung M.C. Hauser C. (1995) Requirement for neuregulin receptor erbB-2 in neural and cardiac development. Nature 378: 394–398.
47. Lethaby A.E. O'Neill M.A. Mason B.H. Holdaway I.M. Harvey V.J. (1996) Overall survival from breast cancer in women pregnant or lactating at or after diagnosis. Auckland Breast Cancer Study Group. Int J Cancer 67: 751–755.
48. Levy S. Fayez I. Taguchi N. Han J.Y. Aiello J. Matsui D. et al (2009) Pregnancy outcome following in utero exposure to bisphosphonates. Bone 44: 428–430.
49. Loibl, S., Boog, N.N., Ring, A.E., Crivellari, D., Fehm, T., Heinrigs, M. et al. (2010) Breast cancer during pregnancy – a prospective and retrospective European registry (GBG-20/BIG02-03). Proceedings of the European Breast Cancer Conference; 2010, abstract.
50. Loibl S. von Minckwitz G. Gwyn K. Ellis P. Blohmer J.U. Schlegelberger B. et al (2006) Breast carcinoma during pregnancy. International recommendations from an expert meeting. Cancer 106: 237–246.
51. Lösch A. Lahodny J. Petru E. (2001) Possible influence of granulocyte colony-stimulating factor and recombinant human erythropoietin on human chorionic gonadotrophin secretion during chemotherapy for choriocarcinoma. Gynecol Oncol 83: 165–166.
52. Lycette J.L. Dul C.L. Munar M. Belle D. Chui S.Y. Koop D.R. et al (2006) Effect of pregnancy on the pharmacokinetics of Paclitaxel: a case report. Clin Breast Cancer 7: 342–344.
53. Meyer-Wittkopf M. Barth H. Emons G. Schmidt S. (2001) Fetal cardiac effects of doxorubicin therapy for carcinoma of the breast during pregnancy: case report and review of the literature. Ultrasound Obstet Gynecol 18: 62–66.
54. Middleton L.P. Amin M. Gwyn K. Theriault R. Sahin A. (2003) Breast carcinoma in pregnant women: assessment of clinicopathologic and immunohistochemical features. Cancer 98: 1055–1060.
55. Mir O. Berveiller P. Goffinet F. Treluyer J.-M. Serreau R. Goldwasser F. et al (2010) Taxanes for breast cancer during pregnancy: a systematic review. Ann Oncol 21: 425–433.
56. Morris P.G. King F. Kennedy M.J. (2009) Cytotoxic chemotherapy for pregnancy-associated breast cancer: single institution case series. J Oncol Pharm Pract 15: 241–247.
57. Nicholson H.O. (1968) Cytotoxic drugs in pregnancy. Review of reported cases. J Obstet Gynaecol Br Commonw 75: 307–312.
58. Nieto Y. Santisteban M. Aramendía J.M. Fernández-Hidalgo O. García-Manero M. López G. (2006) Docetaxel administered during pregnancy for inflammatory breast carcinoma. Clin Breast Cancer 6: 533–534.
59. Nugent P. O'Connell T.X. (1985) Breast cancer and pregnancy. Arch Surg 120: 1221–1224.
60. Oksüzoglu B. Güler N. (2002) An infertile patient with breast cancer who delivered a healthy child under adjuvant tamoxifen therapy. Eur J Obstet Gynecol Reprod Biol 104: 79–80.
61. Pant S. Landon M.B. Blumenfeld M. Farrar W. Shapiro C.L. (2008) Treatment of breast cancer with trastuzumab during pregnancy. J Clin Oncol 26: 1567–1569.
62. Partridge A.H. Garber J.E. (2000) Long-term outcomes of children exposed to antineoplastic agents in utero. Semin Oncol 27: 712–726.
63. Paskulin G.A. Gazzola Zen P.R. de Camargo Pinto L.L. Rosa R. Graziadio C. (2005) Combined chemotherapy and teratogenicity. Birth Defects Res A Clin Mol Teratol 73: 634–637.
64. Peccatori F.A. Azim H.A. Jr Scarfone G. Gadducci A. Bonazzi C. Gentilini O. et al (2009) Weekly epirubicin in the treatment of gestational breast cancer. Breast Cancer Res Treat 115: 591–594.
65. Petrek J.A. (1994) Breast cancer during pregnancy. Cancer 74(1 Suppl): 518–527.
66. Potluri V. Lewis D. Burton G.V. (2006) Chemotherapy with taxanes in breast cancer during pregnancy: case report and review of the literature. Clin Breast Cancer 7: 167–170.
67. Press M.F. Cordon-Cardo C. Slamon D.J. (1990) Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 5: 953–962.
68. Ranstam J. Janzon L. Olsson H. (1990) Rising incidence of breast cancer among young women in Sweden. Br J Cancer 61: 120–122.
69. Redmond G.P. (1985) Physiological changes during pregnancy and their implications for pharmacological treatment. Clin Invest Med 8: 317–322.
70. Ring A.E. Smith I.E. Ellis P.A. (2005 a) Breast cancer and pregnancy. Ann Oncol 16: 1855–1860.
71. Ring A.E. Smith I.E. Jones A. Shannon C. Galani E. Ellis P.A. (2005 b) Chemotherapy for breast cancer during pregnancy: an 18-year experience from five London teaching hospitals. J Clin Oncol 23: 4192–4197.
72. Robinson A.A. Watson W.J. Leslie K.K. (2007) Targeted treatment using monoclonal antibodies and tyrosine-kinase inhibitors in pregnancy. Lancet Oncol 8: 738–743.
73. Rodríguez-Pinilla E. Martínez-Frías M.L. (1998) Corticosteroids during pregnancy and oral clefts: a case-control study. Teratology 58: 2–5.
74. Saunders C.M. (1999) Breast cancer in pregnancy. In: Ed. Shaugn O'Brien P. MacLean A. (eds). Hormones and Cancer, Royal College of Obstetricians and Gynaecologists Press: London, 312–321.
75. Schapira D.V. Chudley A.E. (1984) Successful pregnancy following continuous treatment with combination chemotherapy before conception and throughout pregnancy. Cancer 54: 800–803.
76. Sekar R. Stone P.R. (2007) Trastuzumab use for metastatic breast cancer in pregnancy. Obstet Gynecol 110: 507–510.
77. Shrim A. Garcia-Bournissen F. Maxwell C. Farine D. Koren G. (2007) Favorable pregnancy outcome following trastuzumab (Herceptin) use during pregnancy-case report and updated literature review. Reprod Toxicol 23: 611–613.
78. Smit J.W. Huisman M.T. van Tellingen O. Wiltshire H.R. Schinkel A.H. (1999) Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. J Clin Invest 104: 1441–1447.
79. Smith L.H. Dalrymple J.L. Leiserowitz G.S. Danielsen B. Gilbert W.M. (2001) Obstetrical deliveries associated with maternal malignancy in California, 1992 through 1997. Am J Obstet Gynecol 184: 1504–1513.
80. Sullivan C.A. Johnson C.A. Roach H. Martin R.W. Stewart D.K. Morrison J.C. (1996) A pilot study of intravenous ondansetron for hyperemesis gravidarum. Am J Obstet Gynecol 174: 1565–1568.
81. Tewari K. Bonebrake R.G. Asrat T. Shanberg A.M. (1997) Ambiguous genitalia in infant exposed to tamoxifen in utero. Lancet 350: 183–184.
82. Tincello D.G. Johnstone M.J. (1996) Treatment of hyperemesis gravidarum with the 5-HT3 antagonist ondansetron (Zofran). Postgrad Med J 72: 688–689.
83. Turchi J.J. Villasis C. (1988) Anthracyclines in the treatment of malignancy in pregnancy. Cancer 61: 435–440.
84. Ventura S.J. (1989) First birth to older mothers, 1970–86. Am J Public Health 79: 1675–1677.
85. Wallack M.K. Wolf J.A. Jr Bedwinek J. Denes A.E. Glasgow G. Kumar B. et al (1983) Gestational carcinoma of the female breast. Curr Probl Cancer 7 (9): 1–58.
86. Warraich Q. Smith N. (2009) Herceptin therapy in pregnancy: continuation of pregnancy in the presence of anhydramnios. J Obstet Gynaecol 29: 147–148.
87. Watson W.J. (2005) Herceptin (trastuzumab) therapy during pregnancy: association with reversible anhydramnios. Obstet Gynecol 105: 642–643.
88. Weber-Schoendorfer C. Schaefer C. (2008) Trastuzumab exposure during pregnancy. Reprod Toxicol 25: 390–391.
89. Wen S.W. Liu S. Kramer M.S. Marcoux S. Ohlsson A. Sauvé R. et al (2001) Comparison of maternal and infant outcomes between vacuum extraction and forceps deliveries. Am J Epidemiol 153: 103–107.
90. White T.T. (1954) Carcinoma of the breast and pregnancy: analysis of 920 cases collected from the literature and 22 new cases. Ann Surg 139: 9–18.
91. White T.T. (1955) Prognosis of breast cancer for pregnant and nursing women: analysis of 1413 cases. Surg Gynecol Obstet 100: 661–666.
92. Wiebe V.J. Sipila P.E. (1994) Pharmacology of antineoplastic agents in pregnancy. Crit Rev Oncol Hematol 16: 75–112.
93. Witzel I.D. Müller V. Harps E. Janicke F. Dewit M. (2008) Trastuzumab in pregnancy associated with poor fetal outcome. Ann Oncol 19: 191–192.
94. Woo J.C. Yu T. Hurd T.C. (2003) Breast cancer in pregnancy: a literature review. Arch Surg 138: 91–98.
95. Zemlickis D. Lishner M. Degendorfer P. Panzarella T. Burke B. Sutcliffe S.B. et al (1992 a) Maternal and fetal outcome after breast cancer in pregnancy. Am J Obstet Gynecol 166: 781–787.
96. Zemlickis D. Lishner M. Degendorfer P. Panzarella T. Sutcliffe S.B. Koren G. (1992 b) Fetal outcome after in utero exposure to cancer chemotherapy. Arch Intern Med 152: 573–576.
97. Zemlickis D. Lishner M. Erlich R. Koren G. (1993) Teratogenicity and carcinogenicity in a twin exposed in utero to cyclophosphamide. Teratog Carcinog Mutagen 13 (3): 139–143.